Company Overview and News

 
Exponential Pharma Growth Expected in China by 2022

9h biospace
Not only is the country seen as a lucrative market for drugs, particularly oncology medicines, entities within the country are making heavy investments in the global biotech industry. On Thursday CNBC reported that China had a 2017 pharmaceutical market valued at $122.6 billion, according to data from health-care information company IQVIA (formerly QuintilesIMS). Those numbers are expected to increase significantly.
Upvote Downvote

 
Portfolio Strategy Report: Why Investors Should Build Shares In Bioscience Stocks

18h seekingalpha
Despite the skittish trading behaviors for bioscience stocks in the prior month, we wish to elucidate why this niche is actually ripe for investing.
Upvote Downvote

 
Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators

19h seekingalpha
Shares of Crispr continued to trade further North. The management is gearing up the next growth phase by streamlining its team.
Upvote Downvote

 
Eli Lilly Olumiant Resurrection Story Has Holes - Bloomberg

2018-04-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Gilead Sciences Expects Decline in Earnings in Fiscal 2018

2018-04-19 marketrealist
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
Upvote Downvote

 
Gilead Sciences May Witness Significant Drop in Revenues in 2018

2018-04-18 marketrealist
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.
Upvote Downvote

 
What Analysts Recommend for Gilead Sciences in April 2018

2018-04-18 marketrealist
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. The company reported full-year 2017 revenues close to $26.1 billion, which is a YoY decline of around 14.1%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.
Upvote Downvote

 
SBUX Stock Price - Starbucks Corp. Stock Quote (U.S.: Nasdaq) - MarketWatch

2018-04-17 marketwatch
Starbucks Corp. said Tuesday that, starting next Monday, it will begin asking customers to provide an email address in order to log on to the coffee chain's in-store wifi service. After the one-time request, customers will be connected for all future wifi usage on that device. The company will also use the email to contact customers with news and deals. Starbucks shares are up 1.3% for the past year while the S&P 500 index is up 13.
Upvote Downvote

7
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position

2018-04-17 seekingalpha
Performance of the Core Biotech Model Account is currently tracking just ahead of the IBB and XBI over the same period of time.
Upvote Downvote

 
Your Daily Pharma Scoop: Blueprint Medicines' BLU-667, Gilead Sciences' NASH Data, Celldex's Plunge

2018-04-17 seekingalpha
Today we will discuss Blueprint Medicines (BPMC), which is down more than 12% after reporting data from a phase 1 study with BLU-667 in RET-altered solid tumors. The phase 1 study was a proof-of-concept study.
Upvote Downvote

 
GE rides gene therapy wave with ready-made viral drug factories - Channel NewsAsia

2018-04-17 channelnewsasia
General Electric is raising its bet on biotechnology with the launch of prefabricated manufacturing units for producing virus-based gene and cell therapies, novel anti-cancer treatments and vaccines.
Upvote Downvote

 
How AbbVie Performed in 4Q17 and Fiscal 2017

2018-04-16 marketrealist
AbbVie (ABBV) generated revenue of $7.7 billion in 4Q17 and $6.8 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~11% growth quarter-over-quarter. AbbVie reported revenue of $28.2 billion in fiscal 2017 and $25.6 billion in fiscal 2016, representing ~10% YoY growth.
Upvote Downvote

 
Gilead (GILD) Presents Encouraging Data on NASH Therapies

2018-04-16 zacks
Gilead Sciences, Inc. (GILD - Free Report) announced encouraging data from a proof-of-concept study of experimental combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis ("NASH"). The data were presented at The International Liver Congress 2018 in Paris.
Upvote Downvote

 
Johnson & Johnson’s Revenue Estimates for 1Q18

2018-04-16 marketrealist
As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17.
Upvote Downvote

1
Portfolio Review: Continued Market Outperformance In Q1 2018

2018-04-15 seekingalpha
Integrated BioSci Investing outperformed all benchmarks since inception as we’ve compounded at the 30% rate. For the same period, the XBI, DOW, and IBB procured 27%, 15%, and 9%, respectively.
Upvote Downvote

GILD: Gilead Sciences Analysis and Research Report

2018-03-04 - Asif

Overview Gilead Sciences, Inc. (Gilead, we, its or us), incorporated in Delaware on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, the company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead Sciences has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. The company seek to add to its existing portfolio of products through its internal discovery and clinical development programs and through product acquisition and in-licensing strategies. 2017 Highlights Over the past year, the company continued to bring best-in-class drugs to market that advance the standard of care by off...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 375558103